2022
mHealth Intervention to Improve Treatment Outcomes Among People With HIV Who Use Cocaine: Protocol for a Pilot Randomized Controlled Trial
Ranjit YS, Krishnan A, Ghosh D, Cravero C, Zhou X, Altice FL. mHealth Intervention to Improve Treatment Outcomes Among People With HIV Who Use Cocaine: Protocol for a Pilot Randomized Controlled Trial. JMIR Research Protocols 2022, 11: e28332. PMID: 35254270, PMCID: PMC8938831, DOI: 10.2196/28332.Peer-Reviewed Original ResearchINTERNATIONAL REGISTERED REPORT IDENTIFIERMobile health interventionsAntiretroviral therapyTreatment outcomesHealth interventionsHIV treatment outcomesInstitutional review boardTechnology-based interventionsControlled TrialsHIV servicesMedication adherenceStudy populationElectronic pillboxMulticomponent interventionUse cocaineAdherence behaviorHIVMHealth interventionsFinal enrollmentReview boardStudy designDrug abuse
2021
Costs and impact on HIV transmission of a switch from a criminalisation to a public health approach to injecting drug use in eastern Europe and central Asia: a modelling analysis
Ward Z, Stone J, Bishop C, Ivakin V, Eritsyan K, Deryabina A, Low A, Cepeda J, Kelly SL, Heimer R, Cook R, Altice FL, Litz T, Terlikbayeva A, El-Bassel N, Havarkov D, Fisenka A, Boshnakova A, Klepikov A, Saliuk T, Deshko T, Vickerman P. Costs and impact on HIV transmission of a switch from a criminalisation to a public health approach to injecting drug use in eastern Europe and central Asia: a modelling analysis. The Lancet HIV 2021, 9: e42-e53. PMID: 34895484, PMCID: PMC8762142, DOI: 10.1016/s2352-3018(21)00274-5.Peer-Reviewed Original ResearchConceptsOpioid agonist therapyAgonist therapyAntiretroviral therapyPublic health approachHIV transmissionDrug useDynamic HIV transmission modelHealth approachIncremental cost-effectiveness ratioHIV transmission modelNational InstituteCost-effectiveness ratioCountry-specific costsHIV incidenceUNAIDS 90US National InstitutesART coverageWHO targetPWIDTherapyPay thresholdsInfectious diseasesCost savingsDrug abuseIncremental costModelling the intervention effect of opioid agonist treatment on multiple mortality outcomes in people who inject drugs: a three-setting analysis
Stone J, Degenhardt L, Grebely J, Larney S, Altice FL, Smyrnov P, Rahimi-Movaghar A, Alavi M, Young AM, Havens JR, Miller WC, Hickman M, Vickerman P. Modelling the intervention effect of opioid agonist treatment on multiple mortality outcomes in people who inject drugs: a three-setting analysis. The Lancet Psychiatry 2021, 8: 301-309. PMID: 33640039, PMCID: PMC8255389, DOI: 10.1016/s2215-0366(20)30538-1.Peer-Reviewed Original ResearchConceptsOpioid agonist treatmentDrug-related deathsOAT coverageDrug-related harmAgonist treatmentHepatitis C virus transmissionC virus transmissionOverall health benefitsUK National InstituteNational InstituteHIV 0OAT retentionHIV mortalityInjury 3Opioid dependenceMortality outcomesUS National InstitutesHCV-2Overdose deathsSignificant additional effectIntervention effectsDrug abuseHealth benefitsMortalityDeath
2017
Hepatitis C virus treatment as prevention in an extended network of people who inject drugs in the USA: a modelling study
Zelenev A, Li J, Mazhnaya A, Basu S, Altice FL. Hepatitis C virus treatment as prevention in an extended network of people who inject drugs in the USA: a modelling study. The Lancet Infectious Diseases 2017, 18: 215-224. PMID: 29153265, PMCID: PMC5860640, DOI: 10.1016/s1473-3099(17)30676-x.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAntiviral AgentsChemopreventionCitiesComputer SimulationDisease Transmission, InfectiousFemaleHepatitis CHumansMaleMiddle AgedModels, StatisticalPrevalenceSubstance Abuse, IntravenousSurveys and QuestionnairesTime FactorsTreatment OutcomeUnited StatesYoung AdultConceptsBaseline HCV prevalenceHepatitis C virusHCV prevalenceInjection partnersPrevention strategiesTreatment coverageTransmission of HCVHepatitis C virus (HCV) treatmentHCV elimination strategySuccessful HCV treatmentC virus treatmentInjection drug usersHCV treatment coverageAdditional network memberHCV treatmentActing antiviralsC virusChronic infectionVirus treatmentDrug usersPrevalenceDrug abuseDrugsNational InstitutePrevention
2014
HIV in people reincarcerated in Connecticut prisons and jails: an observational cohort study
Meyer JP, Cepeda J, Springer SA, Wu J, Trestman RL, Altice FL. HIV in people reincarcerated in Connecticut prisons and jails: an observational cohort study. The Lancet HIV 2014, 1: e77-e84. PMID: 25473651, PMCID: PMC4249702, DOI: 10.1016/s2352-3018(14)70022-0.Peer-Reviewed Original ResearchViral suppressionHIV treatment outcomesInhibitor-based regimensObservational cohort studyHIV viral suppressionART regimenCohort studyRetrospective cohortPrimary outcomeViral loadPsychiatric comorbidityTreatment outcomesIdentification of individualsHIVJail detaineesLaboratory databaseTreatment potencyDrug abuseRNA copiesNational InstitutePrison releasePublic healthBlack menIncarceration periodsOutcomes
2006
Buprenorphine and HIV Primary Care: New Opportunities for Integrated Treatment
Khalsa J, Vocci F, Altice F, Fiellin D, Miller V. Buprenorphine and HIV Primary Care: New Opportunities for Integrated Treatment. Clinical Infectious Diseases 2006, 43: s169-s172. PMID: 17109302, DOI: 10.1086/508179.BooksMeSH KeywordsAntiretroviral Therapy, Highly ActiveBuprenorphineDelivery of Health Care, IntegratedFemaleFollow-Up StudiesHealth Services ResearchHIV InfectionsHumansIncidenceMaleNarcotic AntagonistsOpioid-Related DisordersPrimary Health CarePrimary PreventionRisk AssessmentSurvival AnalysisTreatment OutcomeUnited StatesConceptsHuman immunodeficiency virusDrug abuseCare settingsTreatment of HIVHIV primary care settingPrimary HIV care settingsMental Health Services AdministrationHIV primary careProvision of buprenorphineActive antiretroviral therapyHIV care settingsPrimary care settingCollaborative HIV ResearchHealth Services AdministrationAddiction/dependenceAntiretroviral therapyHIV infectionImmunodeficiency syndromeImmunodeficiency virusPrimary careSuccessful treatmentDrug abusersHIV researchDisease controlSubstance abuse
1995
Women Living with Drug Abuse and HIV Disease: Drug Abuse Treatment Access and Secondary Prevention Issues
Weissman G, Melchior L, Huba G, Smereck G, Needle R, McCarthy S, Jones A, Genser S, Cottler L, Booth R, Altice F. Women Living with Drug Abuse and HIV Disease: Drug Abuse Treatment Access and Secondary Prevention Issues. Journal Of Psychoactive Drugs 1995, 27: 401-411. PMID: 8788695, DOI: 10.1080/02791072.1995.10471704.Peer-Reviewed Original ResearchConceptsHIV secondary preventionDrug abuse treatment servicesDrug abuse treatmentSecondary preventionTreatment servicesAbuse treatmentDrug abuseOutpatient drug-free treatmentSecondary prevention issuesDrug-free treatmentDrug abuse treatment systemFirst yearHIV diseaseInjection drugsService utilizationTreatment accessDrug abusersDrug usersTreatment availabilityPositive findingsOutpatient drug abuse treatmentHealth resourcesDrug detoxificationWomenPrevention issuesWomen living with substance abuse and HIV disease: medical care access issues.
Weissman G, Melchior L, Huba G, Altice F, Booth R, Cottler L, Genser S, Jones A, McCarthy S, Needle R. Women living with substance abuse and HIV disease: medical care access issues. Journal Of The American Medical Women's Association 1995, 50: 115-20. PMID: 7657944.Peer-Reviewed Original ResearchConceptsFirst positive HIV testHIV disease coursePositive HIV testHIV testing historyMedical servicesPost-test counselingMental health servicesDrug-using womenUse of healthHIV diseaseHIV testDisease courseDrug abusersTesting historyHealth servicesMen subjectsHealth resourcesSubstance abuseDrug abuseWomenMore womenFirst-year findingsServices AdministrationNational InstituteLongitudinal study